InFo Onkologie

, Volume 21, Issue 1, pp 39–48 | Cite as

Perioperative Behandlungskonzepte

Therapie von Hochrisiko-Weichteilsarkomen bei Erwachsenen

  • Gesa Schuebbe
  • Dorit Di Gioia
  • Falk Roeder
  • Hans Roland Dürr
  • Martin Angele
  • Rolf Issels
  • Lars H. Lindner
zertifizierte fortbildung


Weichteilsarkome stellen Behandler aufgrund ihrer Seltenheit und Vielgestaltigkeit vor große Herausforderungen — sowohl hinsichtlich der Diagnostik als auch der Therapie. Lesen Sie im folgende Beitrag, wie Hochrisiko-Weichteilsarkome vor der Operation behandelt werden sollten.


  1. 1.
    Schütte J et al. Onkopedia Leitlinien: Weichgewebssarkome (Weichteilsarkome) des Erwachsenen. 2017. Abgerufen am 29.01.2018.
  2. 2.
    Schlemmer M et al. Weichteilsarkome im Erwachsenenalter. In: Hiddemann W, Bartram CR (Herausgeber). Die Onkologie. 2010. Heidelberg: Springer Medizin Verlag.Google Scholar
  3. 3.
    von Mehren M et al. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(6):758–86.CrossRefGoogle Scholar
  4. 4.
    Stiller CA et al. Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. Eur J Cancer. 2013;49(3):684–95.CrossRefPubMedGoogle Scholar
  5. 5.
    Gatta G et al. The burden of rare cancers in Europe. Adv Exp Med Biol. 2010;686:285–303.CrossRefPubMedGoogle Scholar
  6. 6.
    Gustafson P et al. Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand. 1994;65(1):47–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Lehnhardt M et al. [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases]. Chirurg. 2009;80(4):341–7.CrossRefPubMedGoogle Scholar
  8. 8.
    ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102–12.CrossRefGoogle Scholar
  9. 9.
    Fletcher CDM, Unni KK, Mertens F. (Herausgeber), Pathology and Genetics of Tumours of Soft Tissue and Bone. World Health Organization Classification of Tumours. 2002. Lyon: IARC Press.Google Scholar
  10. 10.
    Lindner LH (Herausgeber). Tumorzentrum München. MANUAL Knochentumoren und Weichteilsarkom — Empfehlungen zur Diagnostik, Therapie und Nachsorge. 6. Auflage. 2017. Germering: W. Zuckschwerdt Verlag.Google Scholar
  11. 11.
    Coindre JM et al. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med. 2006;130(10):1448–53.PubMedGoogle Scholar
  12. 12.
    Taeger G et al. Isolierte Extremitätenperfusion zur lokalen Tumorkontrolle an den Gliedmaßen. Onkologe. 2009;15(4): 382–88.CrossRefGoogle Scholar
  13. 13.
    Pinedo HM, Verweij J. The treatment of soft tissue sarcomas with focus on chemotherapy: a review. Radiother Oncol. 1986;5(3):193–205.CrossRefPubMedGoogle Scholar
  14. 14.
    van Oosterom AT et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002;38(18):2397–406.CrossRefPubMedGoogle Scholar
  15. 15.
    Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol. 2010;21 Suppl 7:vii270–6.PubMedGoogle Scholar
  16. 16.
    Italiano A et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol. 2010;21(12):2436–41.CrossRefPubMedGoogle Scholar
  17. 17.
    Frustaci S. et al. Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial. J Clin Oncol. 2001;19(5):1238–47.CrossRefPubMedGoogle Scholar
  18. 18.
    Ohne Autor. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647–54.CrossRefGoogle Scholar
  19. 19.
    Pervaiz N et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Woll PJ et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Gortzak E et al. A randomised phase II study on neo-adjuvant chemotherapy for ‚high-risk‘ adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096–103.CrossRefPubMedGoogle Scholar
  22. 22.
    Meric F et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 2002;95(5):1120–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Kraybill WG et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006;24(4):619–25.CrossRefPubMedGoogle Scholar
  24. 24.
    Issels RD et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2017;18(11):e630.CrossRefPubMedGoogle Scholar
  25. 25.
    Chen Y et al. Radiographic response to neoadjuvant therapy and its impact on scope of surgery and prognosis in stage IIB/III soft tissue sarcomas. BMC Cancer. 2013;11;13:591.Google Scholar
  26. 26.
    Gronchi A et al. sarcomaFull-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial. Ann Oncol. 2016;27(suppl_6);Abstr LBA6_PR.CrossRefGoogle Scholar
  27. 27.
    Gronchi A et al. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Ann Oncol. 2016;27(12):2283–88.CrossRefPubMedGoogle Scholar
  28. 28.
    Gronchi A et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30(8):850–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Gronchi A et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812–22.CrossRefPubMedGoogle Scholar
  30. 30.
    Lindner LH, Issels R. Improved Overall Survival (OS) by Neoadjuvant Therapy in Patients (pts) with High-Risk Soft Tissue Sarcoma (HR-STS) of Extremity (E) and Non-extremity (NE). CTOS Annual Meeting. 2017;Abstr #2803418.Google Scholar
  31. 31.
    Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia. 2005;21(8):681–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Zaarur N et al. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res. 2006;66(3):1783–91.CrossRefPubMedGoogle Scholar
  33. 33.
    Noessner E et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol. 2002;169(10):5424–32.CrossRefPubMedGoogle Scholar
  34. 34.
    Milani V et al. Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia. 2002;18(6):563–75.CrossRefPubMedGoogle Scholar
  35. 35.
    Krawczyk PM et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A. 2011;108(24):9851–6.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Issels R et al. Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application. Int J Hyperthermia. 2016;32(1):89–95.CrossRefPubMedGoogle Scholar
  37. 37.
    Roeder F. Neoadjuvante/adjuvante Strahlentherapie beim Weichteilsarkom. Journal Onkologie. 2015;1:41–50.Google Scholar
  38. 38.
    O’Sullivan B et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41.CrossRefPubMedGoogle Scholar
  39. 39.
    Zagars GK et al. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys. 2003;56(2):482–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Roeder F et al. A clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma. BMC Cancer. 2012;12:287.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Pawlik TM et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006;13(4):508–17.CrossRefPubMedGoogle Scholar
  42. 42.
    Eggermont AM et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224(6):756–64; discussion 764-5.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Grünhagen DJ et al. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol. 2006;3(2):94–103.CrossRefPubMedGoogle Scholar
  44. 44.
    Deroose JP et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol. 2011;29(30):4036–44.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Gesa Schuebbe
    • 1
  • Dorit Di Gioia
    • 1
  • Falk Roeder
    • 1
  • Hans Roland Dürr
    • 1
  • Martin Angele
    • 1
  • Rolf Issels
    • 1
  • Lars H. Lindner
    • 1
    • 2
  1. 1.SarKUMZentrum für Knochen- und Weichteiltumoren am Klinikum der Universität MünchenMünchenDeutschland
  2. 2.Med. Klinik und Poliklinik IIIKlinikum der Universität München, Campus GroßhadernMünchenDeutschland

Personalised recommendations